Redeye updates their analysis of Idogen as company approaches clinical phase

Idogen AB (publ) is a company that is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response in the patient. As the company now approaches clinical phase with its most advanced development program IDO 8, Redeye is intensifying their coverage of Idogen and have today published an updated analysis of Idogen AB.

In summary, Redeye's report describes Idogen as a company developing novel treatments where there are large unmedical needs. In the most advanced program, IDO 8, the company has developed a cell therapy for patients with Hemophilia A, who have developed antibodies, a k a "inhibitors". Against their vital factor VIII treatment. The first clinical study within this program has, as previously communicated, obtained regulatory approval in both Sweden and Norway. The first patient is planned to be included in this phase 1/2a study during autumn.

Another example that is highlighted in the analysis of the company's platform is the IDO T-program, where the researchers in the company is working to develop a new cell therapy for patients that are to have a kidney transplant. There is a risk that the patient develops an organ rejection and is currently treated, to minimize the risk, with immunosuppressants for long periods, which may lead to serious side effects. Example of side effects can be e.g. severe infections or cancer. A pre-treatment with Idogen's cell therapy, could counteract the undesired immune reponse that leads to a rejection.

There are several more potential uses for cell therapies from the company as the technology platform is adaptable; as the tolerogenic cells may be adapted to several different types of antigens causing problems for the patient. The usage can thus be expanded to other diseases where the immune system attacks tissues or transplants in an unwanted way.

"Redeye has covered us for a long time and is now making an extensive update as we approach clinical phase" says Christina Herder, acting CEO. "At the same time, we are also intensifying our efforts to reach potential external partners for continued development and commercialization".

Read the analysis in its entirety here https://idogen.com/en/investors/analysts/

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Phone: +46 70374 71 56

Email: christina.herder@idogen.com

Certified Adviser:
The companies Certified Adviser is Vator Securities AB. Contact information: Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm, Email: ca@vatorsec.se.Tel: +46 (0)8-580 065 99

The information was submitted for publication, through the agency of the contact persons set out above, on 5 September 2022 at 16:32 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own

cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com